BCR-ABL-IN-3

Cat. No.:	HY-136526
CAS No.:	2240191-12-0
Molecular Formula:	$C_{20}H_{17}ClF_2N_4O_3S$
Molecular Weight:	466.89
Target:	Bcr-Abl
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BCR-ABL-IN-3 is a potent and irreversible Bcr-Abl inhibitor with an IC_{50} of ≤100 nM for Ba/F_3Bcr-Abl^{T3151}. BCR-ABL-IN-3 has anti-cancer activity[1].
IC_{50} & Target	Ba/F_3Bcr-Abl^{T3151} ≤100 nM (IC_{50})
In Vivo	BCR-ABL-IN-3 (compound 7; 15 mg/kg; twice a day; for 19 days) has good antitumor effect in female NOD/SCID mice of 7-8 weeks weighing 21.8 g with Ba/F_3Bcr-Abl^{T3151} cells[1]. BCR-ABL-IN-3 (2 mg/kg for IV or 20mg/kg for PO) has a C_{max} of 5485 ng/mL and an AUC of 5450 h•ng/mL for IV in male Sprague Dawley rats of 7-8 weeks old weighing 210 g[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Hanyi Wang, et al. (hetero)arylamide compound for inhibiting protein kinase activity. WO2018133826A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA